Difference between revisions of "Dutasteride (Avodart)"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: 5 alpha-reductase | + | Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). Competitively inhibits type 1 and 2 5 alpha-reductase isoenzymes by forming a stable enzyme complex with them.<ref name="insert">[http://us.gsk.com/products/assets/us_avodart.pdf Dutasteride (Avodart) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/dutasteride.pdf Dutasteride (Avodart) package insert (locally hosted backup)]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
Revision as of 23:40, 15 January 2012
General information
Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). Competitively inhibits type 1 and 2 5 alpha-reductase isoenzymes by forming a stable enzyme complex with them.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].